統合システムアプローチは,遅発アルツハイマー病の遺伝子ノードとネットワークを特定します
Bin Zhang1, Chris Gaiteri, Liviu-Gabriel Bodea
1Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. bin.zhang@mssm.edu
Cell
|April 30, 2013
まとめ
この研究は,遅発アルツハイマー病 (LOAD) が脳内の分子ネットワーク,特に免疫およびマイクログリアモジュールを変化させることを明らかにしています. このネットワーク構造は,病気のメカニズムと遺伝子変化への反応を予測するのに役立ちます.
科学分野:
- 神経科学は神経科学である.
- 遺伝学 遺伝学とは
- システム生物学 システム生物学
背景:
- 遅発アルツハイマー病 (LOAD) のような複雑な疾患は,細胞経路内の分子相互作用を伴う.
- 分子ネットワークを通じてこれらの相互作用を理解することは,疾患のメカニズムを特徴づける上で極めて重要です.
研究 の 目的:
- 脳組織における遺伝子調節ネットワークの構築と分析を行い,LOADに関連した分子システムを特定します.
- LOAD病理に関連する特定のネットワーク構造とレギュレータを強調する.
主な方法:
- 1,647人のLOAD患者および認知症のない被験者の死後の脳組織を使用して,遺伝子調節ネットワークの構築.
- 統合的なネットワークベースのアプローチで,LOAD病理学的関連性によるネットワーク構造をランク付けします.
- マウスのマイクログリア細胞を分析して,人間の脳ネットワークからの発見を検証する.
主要な成果:
- LOADは,脳内の分子相互作用構造の特定の部分を再構成することが示されました.
- 免疫およびマイクログリア特有のモジュールは,ファゴサイトーシス遺伝子が支配し,TYROBPによって調節され,LOAD.で上調されていることが判明しました.
- マウスのマイクログリア実験では,ヒトのTYROBPネットワークと重複する表現変化が確認されました.
結論:
- 遺伝子調節ネットワークの構造は,LOAD病理を理解し,遺伝的混乱に対する反応を予測するのに価値があります.
- 特定された免疫およびマイクログリアモジュールは,LOAD.で疾患モデルをテストするための枠組みを提供します.
関連する概念動画
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
02:26Protein Networks
An organism can have thousands of different proteins, and these proteins must cooperate to ensure the health of an organism. Proteins bind to other proteins and form complexes to carry out their functions. Many proteins interact with multiple other proteins creating a complex network of protein interactions.
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...